Sutro Biopharma, Inc
111 Oyster Point Blvd
South San Francisco
California
94080
United States
Tel: 650.881.6500
Website: http://www.sutrobio.com/
Email: general@sutrobio.com
About Sutro Biopharma, Inc
Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.
Stock Symbol: STRO
Our Purpose Is Our Patients
193 articles about Sutro Biopharma, Inc
-
Sutro Biopharma to Present at the Cowen and Company 40th Annual Health Care Conference
2/27/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Bill Newell, Chief Executive Officer, will present at the Cowen and Company 40th Annual Health Care Conference on Wednesday,
-
Sutro Biopharma Expands Senior Management Team with the Appointments of Vice President of Immunobiology and Vice President of Business Development
2/5/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), today announced the expansion of its senior management team with the appointments of Kristin Bedard, Ph.D., as Vice President of Immunobiology, and Brunilda Shtylla as Vice President of Business Development.
-
Sutro Biopharma to Present at 38th Annual J.P. Morgan Healthcare Conference
1/9/2020
Sutro Biopharma, Inc. announced that the company will present at the 38th Annual J.P. Morgan Healthcare Conference on Thursday, Jan. 16, 2020, at 9:00 AM PST at the Westin St. Francis in San Francisco.
-
Sutro Biopharma Appoints James Panek to Board of Directors
1/8/2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the appointment of James P. Panek to its Board of Directors
-
Sutro Biopharma to Present at the Stifel 2019 Healthcare Conference
11/19/2019
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview and business update at the Stifel 2019 Healthcare Conference on Wednesday
-
Sutro Biopharma Reports Third Quarter 2019 Financial Results and Recent Business Highlights and Developments
11/8/2019
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today reported its financial results for the three and nine months ended September 30, 2019
-
Sutro Biopharma Presents Encouraging Preliminary Clinical Data in Ongoing Phase I Study for STRO-002 Antibody-Drug Conjugate in Patients with Advanced Ovarian Cancer
10/29/2019
Data is being presented as a poster today at AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston
-
Sutro Biopharma Announces Presentation of STRO-002 for the Potential Treatment of Ovarian and Endometrial Cancer at the 2019 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
10/16/2019
Sutro discovered and manufactures STRO-002 using its proprietary XpressCF+™ cell-free protein synthesis technology.
-
Sutro Biopharma to Receive Milestone Payment for Novel Bispecific Antibody Drug Conjugate Targeting Solid Tumors
10/8/2019
Merck KGaA, Darmstadt, Germany Designates Undisclosed Bispecific ADC as Clinical Development Candidate
-
Sutro Biopharma to Present at the H.C. Wainwright 21st Annual Healthcare Conference
9/4/2019
Sutro Biopharma, Inc. announced that Bill Newell, CEO of Sutro Biopharma, will present a corporate overview at the H.C. Wainwright 21st Annual Healthcare Conference on Tuesday, Sept. 10, 2019, at 11:40 AM EDT, in New York City.
-
Sutro Biopharma Reports Second Quarter 2019 Financial Results and Recent Business Highlights and Developments
8/14/2019
Sutro Biopharma, Inc. reported its financial results for the three and six months ended June 30, 2019.
-
Sutro Biopharma to Present at the 2019 Wedbush PacGrow Healthcare Conference
8/8/2019
Sutro Biopharma, Inc. announced that its Chief Business Officer, Stephen Worsley, will present at the 2019 Wedbush PacGrow Healthcare Conference on Tuesday, Aug. 13 at 1:20 p.m. EDT in New York City.
-
Sutro Biopharma Appoints Biopharma Veteran Connie Matsui as Board Chair
6/24/2019
Former Biogen Idec executive to bring additional strategic expertise to Sutro's Board
-
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
6/18/2019
Sutro Biopharma, Inc. announced that Steve Worsley, Chief Business Officer, will present a company overview at the JMP Securities Life Sciences Conference on Thursday, June 20 at 12:30 p.m. ET at the St.
-
Sutro Biopharma Announces Encouraging Interim Phase 1 Safety Data on a Potential First-in-Class Antibody-Drug Conjugate STRO-001 for the Treatment of B-cell Malignancies at the European Hematology Association Congress
6/15/2019
Interim results show STRO-001 was generally well tolerated and anti-tumor activity was observed in two patients with recurrent diffuse large B-cell lymphoma (DLBCL)
-
Sutro Biopharma Announces Presentation at the 2019 European Hematology Association Congress
5/16/2019
Sutro Biopharma, Inc. announced that the company will present at the upcoming European Hematology Association Congress being held June 13-16, 2019, in Amsterdam.
-
Sutro Biopharma Reports First Quarter 2019 Financial Results and Recent Business Highlights and Developments
5/15/2019
Sutro Biopharma, Inc. reported its financial results for the quarter ended March 31, 2019.
-
Sutro Biopharma to Present at the 18th Annual Needham Healthcare Conference
4/4/2019
Sutro Biopharma, Inc. announced that Bill Newell, Chief Executive Officer, will present at the 18th Annual Needham Healthcare Conference on Tuesday, April 9 at 4:50 p.m. ET at the Westin Grand Central Hotel in New York.
-
Public perception of the industry can be a bit confusing. Life Science Leader recently pulled together several biopharma executives for a round table discussion of the biopharma industry’s public perception—generally bad—and what might be able to do about it.
-
Sutro Biopharma Reports Full Year 2018 Financial Results and Recent Business Highlights and Developments
4/1/2019
STRO-001 Ongoing Phase 1 Trial in Myeloma and Lymphoma with Initial Safety Data Expected Mid-2019